Loading clinical trials...
Loading clinical trials...
JACOB: Joint Administration of cDNA for TP53, checkpOint Inhibition and Boost/Hypofractionated Radiation. A Phase 0/1 Study in Children With Recurrent, Progressive or Refractory CNS Malignancies.
Conditions
Interventions
SGT-53
hypofractionated radiotherapy with immunotherapy
+1 more
Locations
1
United States
Children's National Hospital
Washington D.C., District of Columbia, United States
Start Date
July 1, 2025
Primary Completion Date
May 1, 2028
Completion Date
May 1, 2028
Last Updated
June 17, 2025
NCT07346157
NCT04023669
NCT00756340
Lead Sponsor
Children's National Research Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions